Regulation of corticosteroid receptor gene expression in depression and antidepressant action

Journal of Psychiatry and Neuroscience

Volumn 24, Issue 1, 1999, Pages 25-39

  Barden, Nicholas ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Amitriptyline; Antidepressive agents; Corticotropin releasing hormone disorder; Dexamethasone; Disease models, animal; Hypothalamic hormones; Mice, transgenic; Receptors, glucocorticoid

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHLORAMPHENICOL ACETYLTRANSFERASE; COMPLEMENTARY RNA; CORTICOSTEROID RECEPTOR; CORTICOSTERONE; CORTICOTROPIN; DESIPRAMINE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MESSENGER RNA;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DRUG ACTIVITY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HIPPOCAMPUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; RECEPTOR GENE; TRANSGENIC MOUSE;

AMITRIPTYLINE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; GENE EXPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; MICE, TRANSGENIC; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID;

EID: 0032972583     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Jasper MS, Engeland WC. Splanchnic neural activity modulates ultradian and circadian rhythms in adrenocortical secretion in awake rats. Neuroendocrinology 1994;59(2):97-109.
2. Cascio CS, Shinsako J, Dallman MF. The suprachiasmatic nuclei stimulate evening ACTH secretion in the rat. Brain Res 1987;423(1-2):173-8.
3. Szafarczyk A, Alonso G, Ixart G, Malaval F, Assenmacher I. Diurnal-stimulated and stress-induced ACTH release in rats is mediated by ventral noradrenergic bundle. Am J Physiol 1985; 249(2:Pt 1):E219-26.
4. Beaulieu S, Pelletier G, Vaudry H, Barden N. Influence of the central nucleus of the amygdala on the content of corticotropin-releasing factor in the median eminence. Neuroendocrinology 1989;49(3):255-61.
5. Beaulieu S, Di Paolo T, Cote J, Barden N. Participation of the central amygdaloid nucleus in the response of adrenocorticotropin secretion to immobilization stress: opposing roles of the noradrenergic and dopaminergic systems. Neuroendocrinology 1987;45(1):37-46.
6. Jacobson L, Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. [Review] [159 refs]. Endocr Rev 1991;12(2):118-34.
7. Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117(6):2505-11.
8. Miesfeld R, Okret S, Wikstrom AC, Wrange O, Gustafsson JA, Yamamoto KR. Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells. Nature 1984;312(5996):779-81.
9. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237(4812): 268-75.
10. Cintra A, Zoli M, Rosen L, Agnati LF, Okret S, Wikstrom AC, Gustaffsson JA, Fuxe K. Mapping and computer assisted morphometry and microdensitometry of glucocorticoid receptor immunoreactive neurons and glial cells in the rat central nervous system. Neuroscience 1994;62(3):843-97.
11. Funder JW. Corticosteroid receptors and the central nervous system. J Steroid Biochem Mol Biol 1994;49(4-6):381-4.
12. Ratka A, Sutanto W, Bloemers M, de Kloet ER. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 1989;50(2):117-23.
13. de Kloet ER. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 1991;12:95-164
14. Bradbury MJ, Akana SF, Cascio CS, Levin N, Jacobson L, Dallman MF. Regulation of basal ACTH secretion by corticosterone is mediated by both type I (MR) and type II (GR) receptors in rat brain. [Review] [66 refs]. J Steroid Biochem Mol Biol 1991;40(1-3):133-42.
15. Dallman MF, Levin N, Cascio CS, Akana SF, Jacobson L, Kuhn RW. Pharmacological evidence that the inhibition of diurnal adrenocorticotropin secretion by corticosteroids is mediated via type I corticosterone-preferring receptors. Endocrinology 1989;124(6):2844-50.
16. Regestein QR, Rose Li, Williams GH. Psychopathology in Cushing's syndrome. Arch Intern Med 1972;130(1):114-7.
17. Carroll, Curtis GC, Mendels J. Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry 1976;33(9):1039-44..
18. von Bardeleben U, Holsboer F. Cortisol response to a combined dexamethasone-human corticotrophin-releasing hormone challenge in patients with depression. J Neuroendocrinol 1989;1:485-488.
19. Murphy BE. Steroids and depression. [Review] [186 refs]. J Steroid Biochem Mol Biol 1991;38(5):537-59.
20. Linkowski P, Kerkhofs M, Van Onderbergen A, Hubain P, Copinschi G, L'Hermite-Baleriaux M, Leclercq R, Brasseur M, Mendlewicz J, Van Cauter E. The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania. Arch Gen Psychiatry 1994;51(8):616-24.
21. Holsboer F, von Bardeleben U, Gerken A, Stalla GK, Muller OA. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression [letter]. N Engl J Med 1984;311(17):1127.
22. Holsboer F, Gerken A, Stalla GK, Muller OA. ACTH, cortisol, and corticosterone output after ovine corticotropin-releasing factor challenge during depression and after recovery. Biol Psychiatry 1985;20(3):276-86.
23. Holsboer F, Gerken A, von Bardeleben U, Grimm W, Beyer H, Muller OA, Stalla GK. Human corticotropin-releasing hormone in depression-correlation with thyrotropin secretion following thyrotropin-releasing hormone. Biol Psychiatry 1986;21(7):601-11.
24. Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerinos P, Schulte H, Oldfield E, Loriaux DL. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 1984;141(5):619-27.
25. Holsboer, F., Spengler, D. and Heuser, I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res 1992;93:385-417.
26. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?. [Review] [267 refs]. Brain Res Brain Res Rev 1990;15(2):71-100.
27. Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. [Review] [577 refs]. Pharmacol Rev 1991;43(4):425-73.
28. Torpy DJ, Grice JE, Hockings GI, Walters MM, Crosbie GV, Jackson RV. Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans. J Clin Endocrinol Metab 1994;79(1):140-4.
29. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226(4680):1342-4.
30. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994;60(4):436-44.
31. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988;45(6):577-9.
32. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986;314(21):1329-35.
33. von Bardeleben U, Stalla GK, Muller OA, Holsboer F. Blunting of ACTH response to human CRH in depressed patients is avoided by metyrapone pretreatment. Biol Psychiatry 1988;24(7):782-6.
34. Lisansky J, Peake GT, Strassman RJ, Qualls C, Meikle AW, Risch SC, Fava GA, Zownir-Brazis M, Hochla P, Britton D. Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pretreated with metyrapone [published erratum appears in Arch Gen Psychiatry 1989;46(12):1152]. Arch Gen Psychiatry 1989;46(7):641-9.
35. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994;28(4):341-56.
36. Holsboer-Trachsler E, Stohler R, Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Res 1991;38(2):163-71.
37. Young EA, Haskett RF, Murphy-Weinberg V, Watson SJ, Akil H. Loss of glucocorticoid fast feedback in depression [see comments]. Arch Gen Psychiatry 1991;48(8):693-9.
38. Gotthardt U, Schweiger U, Fahrenberg J, Lauer CJ, Holsboer F, Heuser I. Cortisol, ACTH, and cardiovascular response to a cognitive challenge paradigm in aging and depression. Am J Physiol 1995;268(4:Pt 2):Pt 2):R865-73.
39. Heuser IJ, Gotthardt U, Schweiger U, Schmider J, Lammers CH, Dettling M, Holsboer F. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol Aging 1994;15(2):227-31.
40. Whalley LJ, Borthwick N, Copolov D, Dick H, Christie JE, Fink G. Glucocorticoid receptors and depression. BMJ (Clin Res Ed) 1986;292(6524):859-61.
41. Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch Gen Psychiatry 1983;40(5):493-500.
42. Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness. Normalisation of test result compared with clinical improvement. J Affect Disord 1982;4(2):93-101.
43. Shimoda K, Yamada N, Ohi K, Tsujimoto T, Takahashi K, Takahashi S. Chronic administration of tricyclic antidepressants suppresses hypothalamo-pituitary-adrenocortical activity in male rats. Psychoneuroendocrinology 1988;13(5):431-40.
44. Pepin MC, Beaulieu S, Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 1989;6(1):77-83.
45. Peiffer A, Veilleux S, Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 1991;16(6): 505-15.
46. Pepin MC, Pothier F, Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 1992;355(6362):725-8.
47. Reul JM, Stec I, Soder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993;133(1):312-20.
48. Gorman C. High efficiency gene transfer into mammalian cells. In: Glover DM (editor). DNA cloning, Vol. 2. Oxford (England): IRL Press; 1985. p. 143-90.
49. van der Eb AJ, Graham FL. Assay of transforming activity of tumor virus DNA. Method Enzymol 1980;65(1):826-39.
50. Pepin MC, Govindan MV, Barden N. Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol Pharmacol 1992;41(6):1016-22.
51. Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1982;1(4):327-41.
52. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
53. Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 1982;2(9):1044-51.
54. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18(24):5294-9.
55. Farmer SR, Wan KM, Ben-Ze'ev A, Penman S. Regulation of actin mRNA levels and translation responds to changes in cell configuration. Mol Cell Biol 1983;3(2):182-9.
56. Kramer CY. Extension of multiple range tests to group means with unequal number of replications. Biometrics 1956;12:307-10.
57. Pepin MC, Barden N. Decreased glucocorticoid receptor activity following glucocorticoid receptor antisense RNA gene fragment transfection. Mol Cell Biol 1991;11(3):1647-53.
58. Stec I, Barden N, Reul JM, Holsboer F. Dexamethasone non-suppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. J Psychiatr Res 1994;28(1):1-5.
59. Richard D, Chapdelaine S, Deshaies Y, Pepin MC, Barden N. Energy balance and lipid metabolism in transgenic mice bearing an antisense GCR gene construct. Am J Physiol 1993; 265(1:Pt 2):R146-50.
60. Rousse I, Beaulieu S, Rowe W, Meaney MJ, Barden N, Rochford J. Spatial memory in transgenic mice with impaired glucocorticoid receptor function. Neuroreport 1997;8(4):841-5.
61. Rochford J, Beaulieu S, Rousse I, Glowa JR, Barden N. Behavioral reactivity to aversive stimuli in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: effects of diazepam and FG-7142. Psychopharmacology (Berl) 1997;132(2):145-52.
62. Montkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, Engelmann M, Reul JM, Landgraf R, Holsboer F. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol 1995;7(11):841-5.
63. Young EA, Haskett RF, Grunhaus L, Pande A, Weinberg VM, Watson SJ, Akil H. Increased evening activation of the hypothalamic-pituitary-adrenal axis in depressed patients. Arch Gen Psychiatry 1994;51(9):701-7.
64. Barden N. Corticosteroid receptor modulation in transgenic mice. [Review] [33 refs]. Ann N Y Acad Sci 1994;746:89-98.
65. Barden N, Stec IS, Montkowski A, Holsboer F, Reul JM. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology 1997;66(3):212-20.
66. Pepin MC, Pothier F, Barden N. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol 1992;42(6):991-5.
67. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11(1):47-60.
68. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987;92(2):180-5.
69. Porsolt RD, Bertin A, Jalfre M. "Behavioural despair" in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 1978;51(3):291-4.
70. Payvar F, DeFranco D, Firestone GL, Edgar B, Wrange O, Okret S, Gustafsson JA, Yamamoto KR. Sequence-specific binding of glucocorticoid receptor to MTV DNA at sites within and upstream of the transcribed region. Cell 1983; 35(2:Pt 1):381-92.
71. Guthrie S, Lane EA, Linnoila M. Monitoring of plasma drug concentrations in clinical psychopharmocology. In: Meltzer HY (editor). Psychopharmacology: the third generation of progress. New York: Raven Press; 1987. p. 1323-38.
72. Linkowski P, Mendlewicz J, Leclercq R, Brasseur M, Hubain P, Golstein J, Copinschi G, Van Cauter E. The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness. J Clin Endocrinol Metab 1985;61(3):429-38.
73. Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukushima DK, Gallagher TF. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 1973;28(1):19-24.
74. Mortola JF, Liu JH, Gillin JC, Rasmussen DD, Yen SS. Pulsatile rhythms of adrenocorticotropin (ACTH) and cortisol in women with endogenous depression: evidence for increased ACTH pulse frequency. J Clin Endocrinol Metab 1987;65(5):962-8.
75. Carroll BJ, Martin FI, Davies B. Resistance to suppression by dexamethasone of plasma 11-O.H.C.S. levels in severe depressive illness. BMJ 1968;3(613):285-7.
76. Carroll BJ. The dexamethasone suppression test for melancholia. Br J Psychiatry 1982;140:292-304.
77. Szigethy E, Conwell Y, Forbes NT, Cox C, Caine ED. Adrenal weight and morphology in victims of completed suicide. Biol Psychiatry 1994;36(6):374-80.
78. Amsterdam JD, Marinelli DL, Arger P, Winokur A. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: a pilot study. Psychiatry Res 1987;21(3):189-97.
79. Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression. A computed tomographic study [see comments]. Arch Gen Psychiatry 1992;49(5):384-7.
80. Lachman HM, Kelsoe JR, Remick RA, Sadovnick AD, Rapaport MH, Lin M, Pazur BA, Roe AM, Saito T, Papolos DF. Linkage studies suggest a possible locus for bipolar disorder near the velo-cardio-facial syndrome region on chromosome 22. Am J Med Genet 1997;74(2):121-8.
81. Suda T, Tozawa F, Yamada M, Ushiyama T, Tomori N, Sumitomo T, Nakagami Y, Demura H, Shizume K. Insulin-induced hypoglycemia increases corticotropin-releasing factor messenger ribonucleic acid levels in rat hypothalamus. Endocrinology 1988;123(3):1371-5.
82. Ban TA. Monoamine uptake inhibitors. Mod Probl Pharmacopsychiatry 1982;18:1-16.
83. Beaulieu S, Barden N. Antidepressant, serotoninergic and glucocorticoid modulation of GR mRNA in hypothalamic neurons. Neuroendocrinol Lett 1987;9:186.
84. Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer H. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994;60(5):509-19.
85. Kitayama I, Janson AM, Cintra A, Fuxe K, Agnati LF, Ogren SO, Harfstrand A, Eneroth P, Gustafsson JA. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. Evidence for selective increases of glucocorticoid receptor immunoreactivity in the locus coeruleus and in 5-hydroxytryptamine nerve cell groups of the rostral ventromedial medulla. J Neural Transm 1988;73(3):191-203.
86. Seckl JR, Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992;55(6):621-6.
87. Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991;87(3):831-7.
88. Hanin I, Frazer A, Croughan J, Davis JM, Katz MM, Koslow SH, Maas JW, Stokes PE. Depression: implications of clinical studies for basic research. Fed Proc 1985;44:85-90.
89. Singh VB, Corley KC, Phan TH, Boadle-Biber MC. Increases in the activity of tryptophan hydroxylase from rat cortex and midbrain in response to acute or repeated sound stress are blocked by adrenalectomy and restored by dexamethasone treatment. Brain Res 1990;516(1):66-76.
90. Kuroda Y, Mikuni M, Ogawa T, Takahashi K. Effect of ACTH, adrenalectomy and the combination treatment on the density of 5-HT2 receptor binding sites in neocortex of rat forebrain and 5-HT2 receptor-mediated wet-dog shake behaviors. Psychopharmacology (Berl) 1992;108(1-2):27-32.
91. 2 receptors in the dorsal hippocampus of male and female rats. Neuroendocrinology 1991;54(5):454-61.
92. Biegon A, Rainbow TC, McEwen BS. Corticosterone modulation of neurotransmitter receptors in rat hippocampus: a quantitative autoradiographic study. Brain Res 1985;332(2):309-14.
93. Young AH, MacDonald LM, St John H, Dick H, Goodwin GM. The effects of corticosterone on 5-HT receptor function in rodents. Neuropharmacology 1992;31(5):433-8.
94. Chalmers DT, Lopez JF, Vazquez DM, Akil H, Watson SJ. Regulation of hippocampal 5-HT1A receptor gene expression by dexamethasone. Neuropsychopharmacology 1994;10(3):215-22.
95. Maes M, Meltzer HYM. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ (editors). Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1994.
96. Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 1994;51(9):687-97.
97. Maes M, Meltzer HY, D'Hondt P, Cosyns P, Blockx P. Effects of serotonin precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal axis function in depression. Psychoneuroendocrinology 1995;20(2):149-67.
98. de Kloet ER, Kovacs GL, Szabo G, Telegdy G, Bohus B, Versteeg DH. Decreased serotonin turnover in the dorsal hippocampus of rat brain shortly after adrenalectomy: selective normalization after corticosterone substitution. Brain Res 1982;239(2):659-63.
99. Seckl JR, Dickson KL, Fink G. Central 5,7-dihydroxytryptamine lesions decrease hippocampal glucocorticoid and mineralocorticoid receptor messenger ribonucleic acid expression. J Neuroendocrinol 1990;2:911-6.
100. Ogawa T, Mikuni M, Kuroda Y, Muneoka K, Mori KJ, Takahashi K. Effects of the altered serotonergic signalling by neonatal treatment with 5,7-dihydroxytryptamine, ritanserin or clomipramine on the adrenocortical stress response and the glucocorticoid receptor binding in the hippocampus in adult rats. J Neural Transm Gen Sect 1994;96(2):113-23.
101. Silva CM, Powell-Oliver FE, Jewell CM, Sar M, Allgood VE, Cidlowski JA. Regulation of the human glucocorticoid receptor by long-term and chronic treatment with glucocorticoid. Steroids 1994;59(7):436-42.
102. Yau JL, Seckl JR. Central 6-hydroxydopamine lesions decrease mineralocorticoid, but not glucocorticoid receptor gene expression in the rat hippocampus. Neurosci Lett 1992;142(2):159-62.
103. Kvetnansky R, Fukuhara K, Pacak K, Cizza G, Goldstein DS, Kopin IJ. Endogenous glucocorticoids restrain catecholamine synthesis and release at rest and during immobilization stress in rats. Endocrinology 1993;133(3):1411-9.
104. Murphy BE, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993;18(5):209-13.